Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

[1]  G. Nakamura,et al.  Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab , 2020, Science.

[2]  A. López-Guillermo,et al.  Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells , 2019, Oncogene.

[3]  G. Gaidano,et al.  Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications , 2019, Leukemia.

[4]  Z. Estrov,et al.  Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. , 2019, Blood.

[5]  Š. Pospíšilová,et al.  Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels , 2018, Leukemia.

[6]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[7]  J. Krepinsky,et al.  Regulation of profibrotic responses by ADAM17 activation in high glucose requires its C-terminus and FAK , 2018, Journal of Cell Science.

[8]  M. Müschen.  Autoimmunity checkpoints as therapeutic targets in B cell malignancies , 2018, Nature Reviews Cancer.

[9]  M. Cragg,et al.  Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? , 2017, Front. Immunol..

[10]  W. Klapper,et al.  Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.

[11]  J. Burke,et al.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Dalla‐Favera,et al.  Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia , 2017, Proceedings of the National Academy of Sciences.

[13]  W. Chan,et al.  CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma , 2015, British journal of haematology.

[14]  C. Fegan,et al.  Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study , 2015, Leukemia.

[15]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[16]  Sudhir V. Shah,et al.  ADAM10 Is the Major Sheddase Responsible for the Release of Membrane-associated Meprin A* , 2014, The Journal of Biological Chemistry.

[17]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[18]  A. Wiestner,et al.  B-cell receptor signaling as a driver of lymphoma development and evolution. , 2013, Seminars in cancer biology.

[19]  C. Klein,et al.  Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models , 2013, Molecular Cancer Therapeutics.

[20]  S. Joel,et al.  Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.

[21]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[22]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[23]  T. Illidge,et al.  Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. , 2011, Blood.

[24]  P. Lichter,et al.  Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2 , 2011, Haematologica.

[25]  C. Klein,et al.  Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell Lines , 2011, PloS one.

[26]  Cathryn M. Gould,et al.  Phospho.ELM: a database of phosphorylation sites—update 2011 , 2010, Nucleic acids research.

[27]  Markus Werner,et al.  Role of PI3K in the generation and survival of B cells , 2010, Immunological reviews.

[28]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[29]  G. Weinmaster,et al.  Selective Use of ADAM10 and ADAM17 in Activation of Notch1 Signaling , 2009, Molecular and Cellular Biology.

[30]  Shigeo Nakamura,et al.  Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. , 2009, Blood.

[31]  K. Horiuchi,et al.  ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. , 2009, Molecular biology of the cell.

[32]  F. Oswald,et al.  The Notch signaling pathway: Transcriptional regulation at Notch target genes , 2009, Cellular and Molecular Life Sciences.

[33]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[34]  B. Hoffman,et al.  Apoptotic signaling by c-MYC , 2008, Oncogene.

[35]  Chi-Ying F. Huang,et al.  PhosphoPOINT: a comprehensive human kinase interactome and phospho-protein database , 2008, ECCB.

[36]  G. Packham,et al.  Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling* , 2008, Journal of Biological Chemistry.

[37]  W. Pear,et al.  Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells , 2007, Proceedings of the National Academy of Sciences.

[38]  G. Mills,et al.  Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[40]  R. Derynck,et al.  Characterization of Growth Factor-induced Serine Phosphorylation of Tumor Necrosis Factor-α Converting Enzyme and of an Alternatively Translated Polypeptide* , 2003, The Journal of Biological Chemistry.

[41]  S R Datta,et al.  14-3-3 inhibits Bad-induced cell death through interaction with serine-136. , 2001, Molecular pharmacology.

[42]  P. Circosta,et al.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. , 1999, Leukemia research.

[43]  T. Soderling,et al.  Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway , 1998, Nature.

[44]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[45]  A. Epstein,et al.  Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines. , 1979, Cancer research.

[46]  P. Cutillas.  Targeted In-Depth Quantification of Signaling Using Label-Free Mass Spectrometry. , 2017, Methods in enzymology.

[47]  A. Tomita.  Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. , 2016, Journal of clinical and experimental hematopathology : JCEH.

[48]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[49]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.